GLP1R and Stroke: Mogensen et al. [24] reported significantly lower event rates for cardiovascular death and combined end point of MI, stroke and CV death among patients treated with DPP-4 inhibitors and GLP-1R agonist in addition to MET, compared to those treated with insulin and SU [24].